Here's Why Indivior Stock Soared 15% Today

Core Viewpoint - Indivior Plc's shares rose by 15.5% following the release of strong third-quarter results and an upgrade in full-year guidance, highlighting the success of its "Indivior Action Agenda" plan and the growth of its key medication, Sublocade [1] Group 1: Financial Performance - Indivior's management reported a 7% increase in U.S. Sublocade sales for the first nine months of 2025 compared to the same period in 2024 [3] - The updated full-year guidance for total Sublocade sales is now projected to be between $825 million and $845 million, an increase from the previous guidance of $765 million to $785 million [3] Group 2: Product Overview - Sublocade is indicated for treating moderate to severe opioid use disorder, offering a monthly dosage system that provides significant benefits over the daily regimen of buprenorphine [2] - The medication's unique delivery system is expected to yield more reliable outcomes for patients suffering from opioid use disorder [7] Group 3: Strategic Initiatives - Indivior aims to achieve $150 million in annual expense savings by 2026 through restructuring and consolidating its operations [5] - The company's three-phase plan includes accelerating Sublocade revenue growth in the U.S. and converting it into earnings and cash flow generation, followed by using the improved financial profile for growth through acquisitions [5][6]